Laverock Therapeutics expands team by 50% and adds a new FD
Laverock significantly grow the team by 50% in last year.
Laverock significantly grow the team by 50% in last year.
Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. by Matthew Moynes, Director at Calculus 06 March 2024 From the very start, the Chancellor appeared to be delivering his budget to a particularly raucous House of Commons. Heightened levels of jeering and frequent interruptions seemed … Continued
Riff Raff strikes TV development deal with Newen Connect with the first project to be a political thriller starring Riff Raff founder Jude Law.
Valuations are always a popular topic. With much discussion about whether we are at the bottom of the current cycle, John Glencross, CEO and Co-Founder of Calculus Capital, who has experienced multiple economic cycles, speaks to Brian Moretta.
Spectral Receives UKCA Authorization for Burn Indication Expected Commercialization 2nd Half 2024.
Tagomics, developers of a cutting-edge platform for comprehensive disease insight and diagnosis, today announces a £6.7m funding round. This achievement follows a £1.6m pre-seed round led by IQ Capital and Start Codon and including grant funding from Innovate UK. The investment will accelerate Tagomics’ scientific research and product development, with the goal of delivering improvements … Continued
Optalitix partner with Quantee, in exciting partnership
Invizius announce the first two patients have been treated at the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility (CRF) with lead product, H-Guard® Priming Solution.
The start of this trial investigating its lead asset OBT076 in Adenoid Cystic Carcinoma (ACC) is a major milestone for OBT.
Boy Swallows Universe has become a hit since landing on Netflix.